Alimera Sciences Inc ALIM:NASDAQ

Last Price$4.39NASDAQ Previous Close - Last Trade as of 3:55PM ET 3/27/20

Today's Change-0.15(3.30%)
Bid (Size)$4.23 (12)
Ask (Size)$24.58 (2)
Day Low / High$3.93 - 4.60
Volume8.5 K
  • Latest Stories
  • Commentary and Analysis
Alimera Sciences' Consensus Outlook for Q1, 2020, and 2021 Earnings Trimmed
11:35PM ET 3/02/2020 MT Newswires

Earnings estimates for Q1 ending March 31, 2020, and the full year forecasts for 2020 and 2021 for the years ending on December 31 for Alimera Sciences Inc...

Alimera Sciences Taps $2.5 Million Loan After Meeting Milestone Target
10:42AM ET 2/24/2020 MT Newswires

Alimera Sciences (ALIM) said on Monday it has drawn down the remaining $2.5 million of the $45 million term loan agreement with investment affiliates...

--Analyst Actions: HC Wainwright Lifts Alimera Sciences' Price Target to $15 From $1, Reiterates Buy Rating
11:31AM ET 11/18/2019 MT Newswires

Price: 5.35, Change: +0.60, Percent Change: +12.63 ...

Alimera Sciences Expands Iluvien Distribution to Benelux Countries Through Horus Pharma, Shares Up 11%
2:14PM ET 9/12/2019 MT Newswires

Alimera Sciences (ALIM) said on Thursday it has struck a deal that would allow Horus Pharma to distribute Iluvien for diabetic macular edema and...

Alimera Sciences Plans Reverse Stock Split to Boost Share Price in Line With Nasdaq Rules
9:09AM ET 9/05/2019 MT Newswires

Alimera Sciences (ALIM) said its board approved a reverse split of its common stock to allow the pharmaceutical company to attain the minimum $1 per share...

Alimera Sciences Q2 Loss Widens By More Than Expected; Revenue Misses Estimate
6:30AM ET 7/30/2019 MT Newswires

Alimera Sciences (ALIM) released its Q2 results late Monday, marking a loss of $0.07 per share that widened from the loss of $0.06 per share a year ago....

UK Regulator Backs Alimera Sciences' Three-Year Uveitis Implant - Shares Up 19% Pre-Bell
8:39AM ET 6/20/2019 MT Newswires

Alimera Sciences (ALIM) said pre-market Thursday that the National Institute for Health and Care Excellence in the UK has recommended funding for lluvien...

Alimera Sciences to Start Selling Iluvien for Treating Eye Disease in Europe in H2
11:43AM ET 6/06/2019 MT Newswires

Alimera Sciences'(ALIM) said it plans to start selling its Iluvien treatment for non-infectious uveitis, a swelling of the eye, in Europe in H2 2019. The...

Analyst Actions: Craig Hallum Initiates Coverage on Alimera Sciences With Buy Rating and $3 PT
10:45AM ET 5/28/2019 MT Newswires

Alimera Sciences' (ALIM) average rating among analysts is a buy, with an average price target of $3. Price: 0.94, Change: +0.07, Percent Change: +8.06 ...

Alimera Sciences' 2020 Earnings Estimate Reduced
11:16PM ET 5/14/2019 MT Newswires

The 2020 forecasted earnings estimate for Alimera Sciences Inc's (NASDAQ:ALIM, Recent Price: 0.92) for the year ending December 31, 2020 has been reduced....